New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Rgenix is raising $11,000,000.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, David Darst played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rgenix

Innovative Science, breakthrough technology, first-in-class treatments. These are the foundations on which Rgenix is built. They are at the core of everything we do. Our top-tier team is focused on developing cutting-edge medicines with the goal of curing cancers of high unmet need and ultimately saving lives. Our discovery platform which can be applied to virtually any tumor type has yielded novel therapeutic targets for several high unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies.

To learn more about Rgenix, visit http://www.rgenix.com/

Contact:
David Darst, Chief Operating Officer
646-856-9261
david@rgenix.com
https://www.linkedin.com/in/david-darst-114b3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved